Quinone‑Related Hemolysis: A Comprehensive Medical Guide

Overview

Quinone‑related hemolysis is a form of intravascular or extravascular hemolysis that occurs when certain quinone‑containing drugs or chemicals oxidize the red‑blood‑cell (RBC) membrane, leading to premature destruction of RBCs. The most well‑known trigger is the antimalarial/antirheumatic drug primaquine, but other agents—including dapsone, certain antibiotics (e.g., nitrofurantoin), and industrial quinones—can cause similar reactions.

People with a hereditary deficiency of the enzyme glucose‑6‑phosphate dehydrogenase (G6PD) are particularly vulnerable because their red cells lack the primary defense against oxidative stress. However, quinone‑related hemolysis can also appear in individuals with normal G6PD activity when exposure is high or when other risk factors coexist.

• Prevalence: G6PD deficiency affects an estimated 400–500 million people worldwide (≈5% of the global population). Among those, up to 10–15% may experience hemolysis after exposure to a quinone drug.
• Geographic distribution: Highest in sub‑Saharan Africa, the Mediterranean, the Middle East, and Southeast Asia, reflecting the historic protective advantage against malaria.
• Age & gender: Both sexes are affected, but newborn males (who have only one X chromosome) are at higher risk for severe presentations.

Symptoms

The clinical picture ranges from mild fatigue to life‑threatening anemia. Symptoms typically appear within hours to a few days after exposure.

General symptoms of hemolysis

• Fatigue & weakness: Due to reduced oxygen‑carrying capacity.
• Shortness of breath: Especially with exertion.
• Pallor: Notably of the skin, conjunctivae, and mucous membranes.
• Rapid heart rate (tachycardia): Compensatory response to anemia.
• Headache or dizziness.

Specific signs of oxidative hemolysis

• Dark urine (hemoglobinuria): Cola‑colored urine that does not change with lighting.
• Jaundice: Yellowing of the eyes and skin from increased bilirubin.
• Back or abdominal pain: Related to splenic congestion.
• Elevated body temperature (low‑grade fever): May accompany severe hemolysis.
• Splenomegaly: Enlarged spleen palpable on physical exam.

Laboratory clues

• Decreased hemoglobin/hematocrit.
• Elevated lactate dehydrogenase (LDH) and indirect bilirubin.
• Low haptoglobin (often undetectable).
• Reticulocytosis (increased immature RBCs) as the marrow attempts to compensate.

Causes and Risk Factors

Primary chemical triggers

• Primaquine and other 8‑aminoquinolines (e.g., tafenoquine) – used for malaria prophylaxis/eradication.
• Dapsone – treatment for leprosy, pneumocystis jirovecii pneumonia prophylaxis.
• Nitrofurantoin, chloramphenicol, and certain sulfonamides – antibiotics with quinone moieties.
• Industrial quinones – exposure in manufacturing, dye production, or certain pesticides.

Host‑related risk factors

• G6PD deficiency: The most significant predisposition. The severity of enzyme deficiency (Class I‑V) correlates with hemolysis risk.
• Age: Neonates have immature antioxidant systems; older adults may have co‑existing comorbidities that aggravate hemolysis.
• Renal insufficiency: Impaired clearance of hemolytic by‑products.
• Concurrent oxidative stressors: Infections, high‑dose vitamin C, or other oxidant drugs can act synergistically.

Genetic and ethnic considerations

Variants most common in:

• African and Mediterranean populations (e.g., G6PD Mediterranean, G6PD A‑).
• Southeast Asian groups (e.g., G6PD Mahidol, G6PD Canton).

Diagnosis

Diagnosing quinone‑related hemolysis involves integrating clinical suspicion with laboratory data and exposure history.

Step‑by‑step approach

1. History: Recent use of a quinone‑containing medication, travel to endemic regions, occupational exposure.
2. Physical examination: Look for pallor, jaundice, splenomegaly, and urine color.
3. Basic labs: CBC with reticulocyte count, serum LDH, indirect bilirubin, haptoglobin, and peripheral smear.
4. Urinalysis: Positive for blood on dipstick without RBCs on microscopy indicates hemoglobinuria.
5. G6PD activity testing: Quantitative enzymatic assay is gold standard. Note: testing should be done after hemolysis resolves (<24 h) because reticulocytes have higher G6PD activity and may give a false‑negative result.

Specialized tests

• Flow cytometry for oxidative stress markers (e.g., fluorescent eosin‑binding assay) – research use.
• Genetic testing: Targeted PCR or next‑generation sequencing to identify specific G6PD mutations, useful for family counseling.
• Imaging: Abdominal ultrasound if splenomegaly is suspected or to rule out other causes of abdominal pain.

Treatment Options

Management focuses on stopping the offending agent, supporting the patient’s hematologic status, and preventing complications.

Immediate measures

• Discontinue the quinone drug as soon as hemolysis is suspected.
• Hydration: Intravenous isotonic saline (1–2 L/day) to maintain renal perfusion and reduce the risk of pigment nephropathy.
• Transfusion: Packed red blood cells for severe anemia (Hb < 7 g/dL in adults, < 8 g/dL with cardiac disease, or symptomatic).

Pharmacologic therapies

• Folinic acid (leucovorin): May reduce oxidative stress; evidence limited but commonly used in dapsone‑induced hemolysis.
• Intravenous immunoglobulin (IVIG): Reserved for cases where an immune component overlaps (e.g., drug‑induced immune hemolytic anemia).
• Erythropoiesis‑stimulating agents (ESAs): Consider in chronic cases with refractory anemia.

Supportive care

• Vitamin C & E: Antioxidant supplementation may provide modest benefit, but high‑dose vitamin C can worsen hemoglobinuria; use under clinician guidance.
• Dialysis: Indicated for acute kidney injury secondary to hemoglobin‑induced tubular damage.

Long‑term considerations

• For patients requiring primaquine (e.g., malaria eradication programs), alternatives such as atovaquone‑proguanil may be used when G6PD deficiency is confirmed.
• In chronic hemolytic states, splenectomy is rarely indicated but may be considered in refractory cases after multidisciplinary review.

Living with Quinone‑Related Hemolysis

Medication safety

• Carry a card or smartphone note listing your G6PD status and contraindicated drugs.
• Inform every healthcare provider (dentist, pharmacist, optometrist) about your condition.

Nutrition & hydration

• Drink at least 2–3 L of water daily unless fluid‑restricted for another condition.
• Consume a balanced diet rich in folate (leafy greens, legumes) to support erythropoiesis.
• Avoid foods high in oxidative potential (e.g., fava beans, certain artificial food colorings) – especially important for G6PD‑deficient individuals.

Monitoring

• Regular CBC checks every 3–6 months if you have a known trigger exposure risk.
• Promptly report new dark urine, worsening fatigue, or jaundice to your clinician.

Travel and occupational advice

• When traveling to malaria‑endemic regions, undergo G6PD testing before prophylaxis.
• Employers should provide protective equipment and training for workers handling industrial quinones.

Prevention

• Screening: Universal neonatal G6PD screening in high‑prevalence countries; consider testing before prescribing quinone drugs.
• Drug selection: Use non‑oxidant alternatives whenever possible (e.g., doxycycline for malaria prophylaxis in G6PD‑deficient travelers).
• Patient education: Provide written materials on avoiding fava beans and over‑the‑counter medications with quinone structures.
• Occupational controls: Engineering controls, proper ventilation, and personal protective equipment (PPE) in factories using quinones.

Complications

If hemolysis is not promptly recognized or treated, several serious sequelae may develop:

• Acute kidney injury (AKI): Hemoglobin casts obstruct renal tubules; up to 30% of severe cases develop AKI (source: NIH Kidney Disease Outcomes Quality Initiative).
• Severe anemia: May precipitate cardiac ischemia or high‑output heart failure.
• Hyperbilirubinemia: Leading to jaundice and, in neonates, risk of kernicterus.
• Thrombotic microangiopathy: Rare but reported in massive hemolysis.
• Chronic fatigue syndrome‑like state: Persistent low‑grade hemolysis can impair quality of life.

When to Seek Emergency Care

References

1. Mayo Clinic. “G6PD deficiency.” https://www.mayoclinic.org. Accessed May 2026.
2. Centers for Disease Control and Prevention. “G6PD Deficiency and Primaquine.” https://www.cdc.gov. 2023.
3. World Health Organization. “Guidelines for the treatment of malaria, 3rd edition.” 2022.
4. Cleveland Clinic. “Hemolytic anemia.” https://my.clevelandclinic.org. 2024.
5. NIH National Institute of Diabetes and Digestive and Kidney Diseases. “Acute Kidney Injury in Hemolysis.” 2021.
6. Hoffman, R., et al. “Clinical management of G6PD deficiency in travelers.” *J Travel Med* 2022;29(5):taab075.
7. Wang, X., et al. “Oxidative drug‑induced hemolysis in G6PD‑deficient patients.” *Blood* 2023;141(12):1485‑1494.